Products

CAS Number：1044872-73-2
Catalog Number:
Chemcial Name:
MW(Molecular Weight)：
MF(Molecular Formula):
SMILES：Introduction:CAS 1044872-73-2, also known as Brigatinib, is a small molecule inhibitor used for the treatment of non-small cell lung cancer (NSCLC). It was developed by ARIAD Pharmaceuticals and was approved by the FDA in 2017 for the treatment of patients with ALK-positive NSCLC.Applications:Brigatinib is used for the treatment of patients with ALK-positive NSCLC who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor. It works by inhibiting the activity of ALK, which is a protein that promotes the growth and survival of cancer cells.Brigatinib has shown promising results in clinical trials and has been found to be effective in patients who have developed resistance to other ALK inhibitors. It has also been found to have a better safety profile compared to other ALK inhibitors.Dosage and Administration:Brigatinib is available in the form of tablets and is taken orally once a day. The recommended dose is 90 mg for the first 7 days, followed by 180 mg once a day. It should be taken with food and should not be crushed or chewed.Side Effects:The most common side effects of Brigatinib include nausea, diarrhea, fatigue, cough, headache, and increased blood pressure. It may also cause serious side effects such as interstitial lung disease, hypertension, and liver problems.Conclusion:Brigatinib is an important addition to the treatment options available for patients with ALK-positive NSCLC. It has been found to be effective in patients who have developed resistance to other ALK inhibitors and has a better safety profile. However, it is important to closely monitor patients for any side effects and to follow the recommended dosage and administration guidelines.